IBN vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is concerning, highlighted by a weak Piotroski F-Score of 2/9, indicating deteriorating operational trends. However, the valuation remains attractive with a PEG ratio of 0.52 and a current price ($27.54) sitting below the growth-based intrinsic value of $31.16. While revenue growth is explosive at 66.90%, the technical trend is currently bearish (0/100) and the 1-year price performance is negative. The stock presents a conflict between strong growth/valuation metrics and poor short-term financial health and price momentum.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
IBN vs JPM: Head-to-Head Comparison
This page compares ICICI Bank Limited (IBN) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.